Importantly, based on the relative successes of the clinical trials for HIE patients, the neuroprotective role of erythropoietin for children with CHD undergoing surgery justifies further investigations since studies of modifiable perioperative strategies have failed to show significant changes in the risk of poor outcomes (Marino et al., 2012). This evidence concerns the gene EPO and coronary artery disorder.